In vitro testing is an important initial step in genotoxicity assessment of cosmetics and personal care products, chemicals (REACH, TSCA and CLP/GHS legislation), pesticides (TSCA, FIFRA, Plant Protection Products and Biocidal Products legislation) and pharmaceuticals (ICH S2 (R1) legislation). The in vitro chromosomal aberration assay is a key testing method for this purpose and the regulatory test method has been clearly defined in OECD 473. The method is used to detect clastogens (i.e., those which cause breaks in chromosomes leading to sections of the chromosome being deleted, added or rearranged), and can evaluate both chromatid-type or chromosome-type aberrations.
Cyprotex is one of the few companies who have expertise in chromosomal aberration and can offer both a non-GLP and GLP service following OECD test method 473.
In the video below, Jessica Sinha, a scientist at our Kalamazoo site in MI, USA, presents on the chromosomal aberration assay, and highlights its importance in regulatory and mechanistic genotoxicity testing.